海南海药涨2.10%，成交额7.66亿元，主力资金净流出8539.09万元

Group 1 - The core viewpoint of the news is that Hainan Haiyao's stock has shown significant volatility, with a year-to-date increase of 72.65% and a recent 5-day increase of 14.23% [1] - As of December 20, 2025, Hainan Haiyao reported a revenue of 640 million yuan, a year-on-year decrease of 20.51%, while the net profit attributable to shareholders was -242 million yuan, reflecting a year-on-year increase of 17.91% [2] - The company has been active in the stock market, appearing on the "Dragon and Tiger List" 10 times this year, with the latest appearance on December 23, where it recorded a net buy of 241 million yuan [1][2] Group 2 - Hainan Haiyao's main business includes traditional Chinese and Western medicines, fine chemical products, chemical raw materials, health products, and related import-export trade, with the revenue composition being 29.93% from other varieties, 25.07% from gastrointestinal products, and 18.60% from medical services [2] - The company has not distributed any dividends in the last three years, with a total payout of 466 million yuan since its A-share listing [3] - As of September 30, 2025, the number of shareholders decreased by 16.14% to 121,500, while the average circulating shares per person increased by 19.25% to 9,599 shares [2]